Adamu Uzairu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adamu Uzairu has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Gideon Adamu Shallangwa
Ahmadu Bello University
34 shared publications - Stephen Eyije Abechi
Ahmadu Bello University Zaria
11 shared publications - Abdullahi Bello Umar
College of Materials Engineering Fujian Agriculture and Forestry University Fuzhou People's Republic of China
7 shared publications - Muhammad Tukur Ibrahim
Department of Chemistry, Faculty of Physical Sciences, Ahmadu Bello University, Zaria, Nigeria
7 shared publications Sani Uba
7 shared publications- Sani Uba
Ahmadu Bello University
7 shared publications
Latest Publications
- 22 September 2026
- Published by Izmir UOD
- p. 80-88
Chemo-Informatics Integration of Novel Anti-Helminthic Agents, Utilizing Molecular Docking, Pharmacokinetics Profiling, and Quantum Chemical Simulations
Soil-transmitted helminthiases (STH), also known as helminthic disease, are caused by parasitic worms that live in the human intestine. They spread through soil or water contaminated by human faeces (poop) that contain the parasite larvae. STH infections are considered neglected tropical diseases (NTDs). About 24% of the world’s population is affected with disease. Some of the drugs used for the treatment of this disease are ivermectin, albendazole and piperazine. Research shows drug resistance in veterinary medicine for the treatment of this disease, as well as similar trends in humans, hence the need for the discovery of new therapeutics. Molecular docking analysis, pharmacokinetics profiling, and DFT computation were carried out on a series of 1,2,4-triazole derivatives for screening standard drug equivalents for this disease. The result of the molecular docking screening identified compound A15 with a mole dock score of -128.98 kcal/mol as a lead compound among the investigated ones and also possessed a good pharmacokinetic profile. The DFT calculations showed that compound A16 is the most reactive with the lowest energy band gap of 3.62 eV among the reported compounds.
- 22 September 2026
- Published by Izmir UOD
- p. 80-88
Chemo-Informatics Integration of Novel Anti-Helminthic Agents, Utilizing Molecular Docking, Pharmacokinetics Profiling, and Quantum Chemical Simulations
Soil-transmitted helminthiases (STH), also known as helminthic disease, are caused by parasitic worms that live in the human intestine. They spread through soil or water contaminated by human faeces (poop) that contain the parasite larvae. STH infections are considered neglected tropical diseases (NTDs). About 24% of the world’s population is affected with disease. Some of the drugs used for the treatment of this disease are ivermectin, albendazole and piperazine. Research shows drug resistance in veterinary medicine for the treatment of this disease, as well as similar trends in humans, hence the need for the discovery of new therapeutics. Molecular docking analysis, pharmacokinetics profiling, and DFT computation were carried out on a series of 1,2,4-triazole derivatives for screening standard drug equivalents for this disease. The result of the molecular docking screening identified compound A15 with a mole dock score of -128.98 kcal/mol as a lead compound among the investigated ones and also possessed a good pharmacokinetic profile. The DFT calculations showed that compound A16 is the most reactive with the lowest energy band gap of 3.62 eV among the reported compounds.
- Open Access
- 30 August 2026
- Published by Elsevier in SSRN Electronic Journal
Discovery of Potential Anti-Tuberculosis Agents Through Computer-Aided Drug Design: QSAR, DFT, Molecular Docking, ADMET Predictions and Molecular Dynamics Simulation
Tuberculosis is a tropical and a multi-drug resistant disease, causing millions of deaths and without any its pathogen, mycobacterium has developed resistance to several key antibiotics, which results in the emergence of extensively drug-resistant (XDR) and multidrug-resistant (MDR) strains. This research aimed at employing QSAR, molecular docking, MD simulation, and other analysis in order to come up with a promising compound that may help to change the current situation. Outcomes from this study showed highly hopeful results, which indicates that the chosen model developed, model 1 exhibits a predictive power that is dependable and confirmed to be a model that is most successful than the other three models, with validation metrics, including R2trn =0.927, R2adj = 0.910, Q2cv =0.874, and R2ext = 0.867. Furthermore, the p-values, mean effect values, and the Y-scrambling test also confirmed that model 1 is the most significant and robust of the model descriptors selected. The impact and reliability of the selected descriptors of the model were validated by these analyses, which strengthen its predictive abilities. Docking studies revealed that, excellent interactions within the active region of gyrB (3ZKB) were demonstrated by an analogue compound 17a when compared to both the template, other analogues and the Isoniazid drug, suggesting potential compounds 17a to be the most effective enzyme target. Complex1 (compound 17a-3ZKB) MD simulations results revealed an outstanding stability, demonstrated by several analyses. This recommended that it holds a promise as potential treatment for tuberculosis.
- 30 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDiscovery of Potential Anti-Tuberculosis Agents Through Computer-Aided Drug Design: QSAR, DFT, Molecular Docking, ADMET Predictions and Molecular Dynamics Simulation
Tuberculosis is a tropical and a multi-drug resistant disease, causing millions of deaths and without any its pathogen, mycobacterium has developed resistance to several key antibiotics, which results in the emergence of extensively drug-resistant (XDR) and multidrug-resistant (MDR) strains. This research aimed at employing QSAR, molecular docking, MD simulation, and other analysis in order to come up with a promising compound that may help to change the current situation. Outcomes from this study showed highly hopeful results, which indicates that the chosen model developed, model 1 exhibits a predictive power that is dependable and confirmed to be a model that is most successful than the other three models, with validation metrics, including R2trn =0.927, R2adj = 0.910, Q2cv =0.874, and R2ext = 0.867. Furthermore, the p-values, mean effect values, and the Y-scrambling test also confirmed that model 1 is the most significant and robust of the model descriptors selected. The impact and reliability of the selected descriptors of the model were validated by these analyses, which strengthen its predictive abilities. Docking studies revealed that, excellent interactions within the active region of gyrB (3ZKB) were demonstrated by an analogue compound 17a when compared to both the template, other analogues and the Isoniazid drug, suggesting potential compounds 17a to be the most effective enzyme target. Complex1 (compound 17a-3ZKB) MD simulations results revealed an outstanding stability, demonstrated by several analyses. This recommended that it holds a promise as potential treatment for tuberculosis.
- Open Access
- 16 May 2026
- Published by Elsevier in SSRN Electronic Journal
Comparative ADMET, Docking and Molecular Dynamics Investigation of Novel Urea Scaffolds and Mesotrione for Sustainable Herbicide Development
The upward dominance of herbicide-resistant weeds has intensified the search for new herbicidal agents with improved efficacy, selectivity and environmental compatibility. In this study, a series of substituted urea derivatives were designed and computationally evaluated as potential inhibitors of 4-hydroxyphenylpyruvate dioxygenase (HPPD), a key enzymatic target in weed management. Molecular docking exploration discovered that several of the designated compounds unveiled resilient binding attraction toward the HPPD active points than the commercial herbicide Mesotrione. Among the evaluated derivatives, Compound -2 demonstrated the maximum satisfactory interaction contour with a MolDock score of -166.256Kcal/mol, significantly outperforming Mesotrione (-118.689Kcal/mol). The enhanced binding enactment of the nominated compounds was attributed to promising hydrogen bonding, hydrophobic interactions, aromatic stacking and van der Waals associations indoors of the catalytic central point. In addition, physicochemical, ADMET and radar plot analyses indicated that the majority of the derivatives possessed acceptable agrochemical properties, including balanced lipophilicity, suitable molecular size, moderate solubility and favorable permeability characteristics. Toxicity predictions further suggested improved safety profiles for the selected compounds, with no major indications of carcinogenicity, mutagenicity, skin sensitization, respiratory failure, or eye irritation. To further validate the stability of the ligand-protein systems, molecular dynamics simulations remained accomplished over a 100ns trajectory. The simulation findings demonstrated that Compound -2 maintained superior conformational stability and stronger interaction persistence within the HPPD active site compared with Mesotrione. This was evidenced by lower RMSD and RMSF fluctuations, stable solvent accessibility of surface area (SASA), consistent radius of gyration (Rg) values, and sustained hydrogen bond interactions through the simulation period. In contrast, the Mesotrione complex exhibited greater structural fluctuations and weaker dynamic stability. Collectively, the integrated docking, ADMET, toxicity and molecular dynamics results identify Compound -2 as a promising lead scaffold with enhanced inhibitory potential, favorable physicochemical behavior, improved predicted safety and strong structural stability. These findings support the potential application of substituted urea derivatives as next-generation HPPD-targeting herbicidal candidates for sustainable weed management strategies.Bottom of Form
- 16 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessComparative ADMET, Docking and Molecular Dynamics Investigation of Novel Urea Scaffolds and Mesotrione for Sustainable Herbicide Development
The upward dominance of herbicide-resistant weeds has intensified the search for new herbicidal agents with improved efficacy, selectivity and environmental compatibility. In this study, a series of substituted urea derivatives were designed and computationally evaluated as potential inhibitors of 4-hydroxyphenylpyruvate dioxygenase (HPPD), a key enzymatic target in weed management. Molecular docking exploration discovered that several of the designated compounds unveiled resilient binding attraction toward the HPPD active points than the commercial herbicide Mesotrione. Among the evaluated derivatives, Compound -2 demonstrated the maximum satisfactory interaction contour with a MolDock score of -166.256Kcal/mol, significantly outperforming Mesotrione (-118.689Kcal/mol). The enhanced binding enactment of the nominated compounds was attributed to promising hydrogen bonding, hydrophobic interactions, aromatic stacking and van der Waals associations indoors of the catalytic central point. In addition, physicochemical, ADMET and radar plot analyses indicated that the majority of the derivatives possessed acceptable agrochemical properties, including balanced lipophilicity, suitable molecular size, moderate solubility and favorable permeability characteristics. Toxicity predictions further suggested improved safety profiles for the selected compounds, with no major indications of carcinogenicity, mutagenicity, skin sensitization, respiratory failure, or eye irritation. To further validate the stability of the ligand-protein systems, molecular dynamics simulations remained accomplished over a 100ns trajectory. The simulation findings demonstrated that Compound -2 maintained superior conformational stability and stronger interaction persistence within the HPPD active site compared with Mesotrione. This was evidenced by lower RMSD and RMSF fluctuations, stable solvent accessibility of surface area (SASA), consistent radius of gyration (Rg) values, and sustained hydrogen bond interactions through the simulation period. In contrast, the Mesotrione complex exhibited greater structural fluctuations and weaker dynamic stability. Collectively, the integrated docking, ADMET, toxicity and molecular dynamics results identify Compound -2 as a promising lead scaffold with enhanced inhibitory potential, favorable physicochemical behavior, improved predicted safety and strong structural stability. These findings support the potential application of substituted urea derivatives as next-generation HPPD-targeting herbicidal candidates for sustainable weed management strategies.Bottom of Form
- 27 December 2025
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 15 (1) , 18
From scaffold to candidate: an integrated machine Learning, QSAR, docking, and molecular dynamics framework for the rational design of IRAK4 inhibitors in diffuse large B-cell lymphoma
- 27 December 2025
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 15 (1) , 18
From scaffold to candidate: an integrated machine Learning, QSAR, docking, and molecular dynamics framework for the rational design of IRAK4 inhibitors in diffuse large B-cell lymphoma
- 26 November 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (3) , 195
Computational optimization of MALT1 inhibitors against DLBCL: a QSAR-guided molecular docking and dynamics study
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a critical effector in constitutive NF-κB signalling, driving oncogenesis in activated B-cell-like diffuse large B-cell lymphoma. Here, we employed an integrated computational strategy to design and optimize small-molecule MALT1 inhibitors. A statistically validated Quantitative structure–activity relationship model (R2 = 0.86, Q2 = 0.82, CCC = 0.90) identified descriptors linked to potency, and docking simulations revealed binding affinities between − 8.6 and − 9.6 kcal/mol. Among the MI-2, a selective small-molecule inhibitor of MALT1 analogues, compound 14 combined favourable docking affinity (− 8.9 kcal/mol) with strong pharmacokinetics, which guided rational optimization. The derivative 14f emerged as the most promising scaffold, achieving improved intestinal absorption (96.9%), favourable clearance (0.43 log ml/min/kg), non-mutagenicity, and the strongest binding affinity (− 9.6 kcal/mol). Molecular dynamics simulations confirmed the stability of the 14f–MALT1 complex, with protein backbone RMSD maintained within 3 Å and ligand fluctuations below 1 Å over 100 ns. Collectively, these results highlight compound 14f as a viable lead scaffold for MALT1 inhibition in DLBCL. As this study is purely computational, experimental validation is required to confirm these findings.
- 26 November 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (3) , 195
Computational optimization of MALT1 inhibitors against DLBCL: a QSAR-guided molecular docking and dynamics study
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a critical effector in constitutive NF-κB signalling, driving oncogenesis in activated B-cell-like diffuse large B-cell lymphoma. Here, we employed an integrated computational strategy to design and optimize small-molecule MALT1 inhibitors. A statistically validated Quantitative structure–activity relationship model (R2 = 0.86, Q2 = 0.82, CCC = 0.90) identified descriptors linked to potency, and docking simulations revealed binding affinities between − 8.6 and − 9.6 kcal/mol. Among the MI-2, a selective small-molecule inhibitor of MALT1 analogues, compound 14 combined favourable docking affinity (− 8.9 kcal/mol) with strong pharmacokinetics, which guided rational optimization. The derivative 14f emerged as the most promising scaffold, achieving improved intestinal absorption (96.9%), favourable clearance (0.43 log ml/min/kg), non-mutagenicity, and the strongest binding affinity (− 9.6 kcal/mol). Molecular dynamics simulations confirmed the stability of the 14f–MALT1 complex, with protein backbone RMSD maintained within 3 Å and ligand fluctuations below 1 Å over 100 ns. Collectively, these results highlight compound 14f as a viable lead scaffold for MALT1 inhibition in DLBCL. As this study is purely computational, experimental validation is required to confirm these findings.
- 9 September 2025
- Published by Izmir UOD
- p. 130-140
Molecular Docking, Drug-Likeness, Pharmacokinetics Properties Prediction and DFT Calculation of Some Dehydroandrogrhapholide and Andrographolides Derivatives as Anti-Hepatitis B Virus Agents
Hepatitis B is a liver infection caused by the hepatitis B virus which usually spread through contact with blood, semen or other body fluids of an infected person. If not treated with caution, hepatitis B virus would gradually grow into a more severe state which results in scarring of the liver, abnormal functionality of the liver and in due time, liver cancer or cirrhosis. In this research, molecular docking studies was carried out on dehydroandrographolide and andrographolide derivatives as anti-hepatitis B virus agents against HBV target (Nucleoside diphosphate kinase) with the pdb ID: 4C6A. The drug-likeness and pharmacokinetic properties of the investigated molecules were also studied. The molecular docking study carried out on the anti-hepatitis B virus agents has explored their theoretical binding affinities with the active sites of the HBV target (Nucleoside diphosphate kinase) in a range of -112.23 to -175.17kcal/mol. Compounds A9 has the highest binding affinity of -175.17kcal/mol out of the 20 dehydroandrographolide and andrographolide derivatives investigated. It formed 4 conventional hydrogen bond interactions with LYS16 (2.77 Å), TYR56 (1.96 Å), ARG109 (3.04 Å) and GLY123 (2.43 Å) amino acid residues. It also formed the carbon-hydrogen bond with LYS16 (2.62 Å), ARG92 (2.62 Å) and ARG92 (2.75 Å) amino acid residues, respectively. It further formed Alkyl hydrophobic bond interaction with ARG92 (4.49 Å), ILE95 (5.18 Å), LEU68 (3.85 Å) and Pi-Alkyl hydrophobic with TYR56 (4.58 Å), HIS59 (5.18 Å), ALA14 (4.82) amino acid residues, respectively. The drug likeness and pharmacokinetics properties prediction performed showed that the studied compounds including the best lead compounds were drug-like in nature with good pharmacokinetics properties and they all have bioavailability score of 0.55, respectively. The DFT studies revealed that compound 2 and 8 among the best five compounds are more reactive having lower energy band gap of 4.3eV, respectively.
- 9 September 2025
- Published by Izmir UOD
- p. 130-140
Molecular Docking, Drug-Likeness, Pharmacokinetics Properties Prediction and DFT Calculation of Some Dehydroandrogrhapholide and Andrographolides Derivatives as Anti-Hepatitis B Virus Agents
Hepatitis B is a liver infection caused by the hepatitis B virus which usually spread through contact with blood, semen or other body fluids of an infected person. If not treated with caution, hepatitis B virus would gradually grow into a more severe state which results in scarring of the liver, abnormal functionality of the liver and in due time, liver cancer or cirrhosis. In this research, molecular docking studies was carried out on dehydroandrographolide and andrographolide derivatives as anti-hepatitis B virus agents against HBV target (Nucleoside diphosphate kinase) with the pdb ID: 4C6A. The drug-likeness and pharmacokinetic properties of the investigated molecules were also studied. The molecular docking study carried out on the anti-hepatitis B virus agents has explored their theoretical binding affinities with the active sites of the HBV target (Nucleoside diphosphate kinase) in a range of -112.23 to -175.17kcal/mol. Compounds A9 has the highest binding affinity of -175.17kcal/mol out of the 20 dehydroandrographolide and andrographolide derivatives investigated. It formed 4 conventional hydrogen bond interactions with LYS16 (2.77 Å), TYR56 (1.96 Å), ARG109 (3.04 Å) and GLY123 (2.43 Å) amino acid residues. It also formed the carbon-hydrogen bond with LYS16 (2.62 Å), ARG92 (2.62 Å) and ARG92 (2.75 Å) amino acid residues, respectively. It further formed Alkyl hydrophobic bond interaction with ARG92 (4.49 Å), ILE95 (5.18 Å), LEU68 (3.85 Å) and Pi-Alkyl hydrophobic with TYR56 (4.58 Å), HIS59 (5.18 Å), ALA14 (4.82) amino acid residues, respectively. The drug likeness and pharmacokinetics properties prediction performed showed that the studied compounds including the best lead compounds were drug-like in nature with good pharmacokinetics properties and they all have bioavailability score of 0.55, respectively. The DFT studies revealed that compound 2 and 8 among the best five compounds are more reactive having lower energy band gap of 4.3eV, respectively.
- Open Access
- 14 March 2025
- Published by Springer Nature in Research Square
Ligand-based design of potent Dipeptidyl Peptidase-IV (DPP-IV) inhibitors in heterocyclic compounds using QSAR, docking, ADMET, and pharmacological profiling for anti-diabetic potential.
ABSTRACT Type 2 Diabetes Mellitus (T2DM) is characterized by high glucose levels in the blood and impaired insulin function, often leading to complications like visual impairment, amputation, and nephropathy. It is a global health challenge and is projected to become the seventh leading cause of mortality. This research aimed to design effective and safer Dipeptidyl Peptidase-IV (DPP-IV) inhibitors as potential T2DM treatments. Five QSAR models were developed, the third model was the most robust, with R² = 0.9904, Q²cv = 0.9836, and R²pred = 0.8989. Based on this model, the newly designed compounds, yielding pIC50 values range 8.1015–8.2760, better than the template (pIC50=8.0), and the reference drug Sitagliptin (pIC50). Docking studies revealed better binding affinities for the newly designed compounds. These compounds exhibited non-harmful profiles and good pharmacokinetics. Using Material Studio v8.0, a Quantitative structure-activity relationship (QSAR) model was constructed and validated through both internal and external assessment procedures. Virtual screening identified a template compound that underwent structural modifications to enhance efficacy. Molecular docking studies using Protein Data Bank data (PDB ID: 3c59) pinpointed active site residues. The pharmacological characteristics of the compounds were evaluated using ADMETlab, SwissADME, and pKCSM. The findings suggest the designed DDP-IV inhibitors are potential candidates for T2DM treatment, giving better results and safety compared to the template and reference drug (Sitagliptin) used in this study. Keywords QSAR, Type 2 Diabetes Mellitus (T2DM), Ligand-based design, Heterocyclic derivatives, Dipeptidyl Peptidase-IV (DPP-IV) inhibitors, Molecular docking, ADMET, and Pharmacokinetic profiling
- 14 March 2025
- Published by Springer Nature in Research Square
Open AccessLigand-based design of potent Dipeptidyl Peptidase-IV (DPP-IV) inhibitors in heterocyclic compounds using QSAR, docking, ADMET, and pharmacological profiling for anti-diabetic potential.
ABSTRACT Type 2 Diabetes Mellitus (T2DM) is characterized by high glucose levels in the blood and impaired insulin function, often leading to complications like visual impairment, amputation, and nephropathy. It is a global health challenge and is projected to become the seventh leading cause of mortality. This research aimed to design effective and safer Dipeptidyl Peptidase-IV (DPP-IV) inhibitors as potential T2DM treatments. Five QSAR models were developed, the third model was the most robust, with R² = 0.9904, Q²cv = 0.9836, and R²pred = 0.8989. Based on this model, the newly designed compounds, yielding pIC50 values range 8.1015–8.2760, better than the template (pIC50=8.0), and the reference drug Sitagliptin (pIC50). Docking studies revealed better binding affinities for the newly designed compounds. These compounds exhibited non-harmful profiles and good pharmacokinetics. Using Material Studio v8.0, a Quantitative structure-activity relationship (QSAR) model was constructed and validated through both internal and external assessment procedures. Virtual screening identified a template compound that underwent structural modifications to enhance efficacy. Molecular docking studies using Protein Data Bank data (PDB ID: 3c59) pinpointed active site residues. The pharmacological characteristics of the compounds were evaluated using ADMETlab, SwissADME, and pKCSM. The findings suggest the designed DDP-IV inhibitors are potential candidates for T2DM treatment, giving better results and safety compared to the template and reference drug (Sitagliptin) used in this study. Keywords QSAR, Type 2 Diabetes Mellitus (T2DM), Ligand-based design, Heterocyclic derivatives, Dipeptidyl Peptidase-IV (DPP-IV) inhibitors, Molecular docking, ADMET, and Pharmacokinetic profiling
- Open Access
- 12 March 2025
- Published by Springer Nature in Research Square
Leveraging In-silico Methods for Laryngeal Cancer Drug Discovery Utilizing QSAR, ligand-base Design, Molecular Docking, and Pharmacokinetic Profiling Approaches.
Objective: This study investigated the design and evaluation of new and more active anti-cancer compounds targeting laryngeal carcinoma Methods: In this study, quantitative structure-activity relationship modeling, ligand-based drug design, molecular docking, and pharmacokinetic studies were utilized in carrying out this research. Result and conclusion: A robust QSAR model was developed, achieving R2adj of 0.8257, R2 of 0.8872 and R²pred of 0.6997, which indicated a reliable predictive capability where the model parameters EE_Dzm and SpAD_DzZ were used in designing five new compounds with compound 3C identified as the most promising candidate, exhibiting a Moldock score of -98.973kcalmol−1, re-rank score of -69.093 kcalmol−1 , predicted activity of 5.349 and a total energy of atoms measured at -64.4248 kcalmol−1, indicating strong binding affinity better than the template 10l and the standard drug. Most importantly, all the five designed compounds adhered to Lipinski's Rule of Five and passed drug-likeness tests, indicating favorable pharmacokinetic profiles.
- 12 March 2025
- Published by Springer Nature in Research Square
Open AccessLeveraging In-silico Methods for Laryngeal Cancer Drug Discovery Utilizing QSAR, ligand-base Design, Molecular Docking, and Pharmacokinetic Profiling Approaches.
Objective: This study investigated the design and evaluation of new and more active anti-cancer compounds targeting laryngeal carcinoma Methods: In this study, quantitative structure-activity relationship modeling, ligand-based drug design, molecular docking, and pharmacokinetic studies were utilized in carrying out this research. Result and conclusion: A robust QSAR model was developed, achieving R2adj of 0.8257, R2 of 0.8872 and R²pred of 0.6997, which indicated a reliable predictive capability where the model parameters EE_Dzm and SpAD_DzZ were used in designing five new compounds with compound 3C identified as the most promising candidate, exhibiting a Moldock score of -98.973kcalmol−1, re-rank score of -69.093 kcalmol−1 , predicted activity of 5.349 and a total energy of atoms measured at -64.4248 kcalmol−1, indicating strong binding affinity better than the template 10l and the standard drug. Most importantly, all the five designed compounds adhered to Lipinski's Rule of Five and passed drug-likeness tests, indicating favorable pharmacokinetic profiles.
- Open Access
- 4 February 2025
- Published by Indonesian Journal of Pharmacy in Indonesian Journal of Cancer Chemoprevention
- Vol. 15 (2) , 108-126
Structure-based Virtual Screening, and Design of Some Lead Compounds as Inhibitors of Kras-G12D of Pancreatic Cancer
Pancreatic cancer is an abnormal cell growth in the pancreas. In 2021, approximately 60,430 individuals were diagnosed in the USA, with the annual increasing incidence rates. Pancreatic cancer is anticipated to become the second leading cause of cancer mortality by 2030. This escalating challenge has prompted a search for innovative therapeutic agents. Virtual screening, a computational technique, was employed to discover novel drug-like compounds from a diverse set of 30 chemical compounds, sourced from the PubChem database. These compounds were evaluated based on some important properties, including pharmacokinetics, lipophilicity, drug-likeness, water-solubility, and physicochemical characteristics. Seventeen compounds emerged as promising candidates for pancreatic cancer treatment. Subsequent molecular docking studies focused on the Kras-G12D protein target and identified Ligand 18 as the leading candidate, exhibiting a binding energy (BE) of -10.5 kcal mol-1 and extensive interactions with the target protein. Additionally, a newly designed compound, D4, displayed an even higher BE of -10.8 kcal mol-1, fitting more effectively into the protein's binding site than existing drugs like Gemcitabine and Irinotecan. All newly designed compounds met the five scientists' rule, indicating favorable drug-likeness and bioavailability. These findings pave the way for developing a new generation of less toxic therapeutic compounds for pancreatic cancer treatment.Keywords: virtual screening, binding energy, kras-G12D, pancreatic cancer, designed compounds.
- 4 February 2025
- Published by Indonesian Journal of Pharmacy in Indonesian Journal of Cancer Chemoprevention
- Vol. 15 (2) , 108-126
Open AccessStructure-based Virtual Screening, and Design of Some Lead Compounds as Inhibitors of Kras-G12D of Pancreatic Cancer
Pancreatic cancer is an abnormal cell growth in the pancreas. In 2021, approximately 60,430 individuals were diagnosed in the USA, with the annual increasing incidence rates. Pancreatic cancer is anticipated to become the second leading cause of cancer mortality by 2030. This escalating challenge has prompted a search for innovative therapeutic agents. Virtual screening, a computational technique, was employed to discover novel drug-like compounds from a diverse set of 30 chemical compounds, sourced from the PubChem database. These compounds were evaluated based on some important properties, including pharmacokinetics, lipophilicity, drug-likeness, water-solubility, and physicochemical characteristics. Seventeen compounds emerged as promising candidates for pancreatic cancer treatment. Subsequent molecular docking studies focused on the Kras-G12D protein target and identified Ligand 18 as the leading candidate, exhibiting a binding energy (BE) of -10.5 kcal mol-1 and extensive interactions with the target protein. Additionally, a newly designed compound, D4, displayed an even higher BE of -10.8 kcal mol-1, fitting more effectively into the protein's binding site than existing drugs like Gemcitabine and Irinotecan. All newly designed compounds met the five scientists' rule, indicating favorable drug-likeness and bioavailability. These findings pave the way for developing a new generation of less toxic therapeutic compounds for pancreatic cancer treatment.Keywords: virtual screening, binding energy, kras-G12D, pancreatic cancer, designed compounds.
- Open Access
- 7 October 2024
- Published by MDPI AG in Nanomaterials
- Vol. 14 (19) , 1609
Templating Iron(III) Oxides on DNA Molecules
Fe(III) oxides were prepared as free nanoparticles and on DNA templates via the precipitation of Fe(III) salts with NaOH in the presence/absence of DNA. Through control of the pH and temperature, FeOOH and Fe2O3 were synthesised. The formation of templated materials FeOOH/DNA and Fe2O3/DNA was confirmed using UV-Vis absorption and FTIR spectra. The direct optical gap of Fe2O3/DNA was estimated as 3.2 eV; the absorption by FeOOH/DNA and Fe2O3/DNA at longer wavelengths is weaker, but consistent with indirect gaps near 2 eV. X-ray photoelectron spectra confirmed the presence of Fe(III) and DNA in the templated samples. Analysis of the X-ray diffraction patterns of both templated and non-templated FeOOH and Fe2O3 demonstrated that the materials were the α-FeOOH and α-Fe2O3 polymorphs with crystallite diameters of the DNA-templated materials estimated as 7.6 nm and 6.8 nm. Transmission electron microscopy showed needle-like crystals of both FeOOH and Fe2O3, but the Fe2O3 contains some globular structures. In contrast, the morphology of FeOOH/DNA and Fe2O3/DNA consists of needle-like crystallites of the respective oxides organised into complex dendritic structures with a length on the 10 μm scale formed by the DNA molecules. Finally, scanned conductance microscopy provided evidence for the conductivity of the FeOOH/DNA after alignment via molecular combing on an Si/SiO2 substrate. Fe2O3/DNA did not exhibit any detectable conductivity.
- 7 October 2024
- Published by MDPI AG in Nanomaterials
- Vol. 14 (19) , 1609
Open AccessTemplating Iron(III) Oxides on DNA Molecules
Fe(III) oxides were prepared as free nanoparticles and on DNA templates via the precipitation of Fe(III) salts with NaOH in the presence/absence of DNA. Through control of the pH and temperature, FeOOH and Fe2O3 were synthesised. The formation of templated materials FeOOH/DNA and Fe2O3/DNA was confirmed using UV-Vis absorption and FTIR spectra. The direct optical gap of Fe2O3/DNA was estimated as 3.2 eV; the absorption by FeOOH/DNA and Fe2O3/DNA at longer wavelengths is weaker, but consistent with indirect gaps near 2 eV. X-ray photoelectron spectra confirmed the presence of Fe(III) and DNA in the templated samples. Analysis of the X-ray diffraction patterns of both templated and non-templated FeOOH and Fe2O3 demonstrated that the materials were the α-FeOOH and α-Fe2O3 polymorphs with crystallite diameters of the DNA-templated materials estimated as 7.6 nm and 6.8 nm. Transmission electron microscopy showed needle-like crystals of both FeOOH and Fe2O3, but the Fe2O3 contains some globular structures. In contrast, the morphology of FeOOH/DNA and Fe2O3/DNA consists of needle-like crystallites of the respective oxides organised into complex dendritic structures with a length on the 10 μm scale formed by the DNA molecules. Finally, scanned conductance microscopy provided evidence for the conductivity of the FeOOH/DNA after alignment via molecular combing on an Si/SiO2 substrate. Fe2O3/DNA did not exhibit any detectable conductivity.